Three of France’s largest hospital networks have joined forces with healthtech startup Kiro to launch OPTIMABIO, an artificial intelligence project designed to improve the prescription of biology tests in clinical settings. The collaborative initiative brings together Assistance Publique-Hôpitaux de Marseille (AP-HM), Hospices Civils de Lyon, and CHU de Limoges to develop and implement AI-assisted decision-making tools for hospital laboratory testing.
Addressing Inefficiencies in Test Prescriptions
The OPTIMABIO project addresses a significant challenge within healthcare systems: the optimization of routine medical decisions related to biology test prescriptions. Hospital laboratories process thousands of test requests daily, and opportunities exist to streamline these procedures while maintaining clinical quality and patient safety. By introducing artificial intelligence into this workflow, the partnership aims to reduce unnecessary testing, improve resource allocation, and ultimately enhance patient outcomes across the three hospital networks.
The funding support from the three hospital institutions demonstrates confidence in Kiro’s technological approach to solving this specific healthcare challenge. Each participating hospital network brings its own clinical expertise and operational requirements to the project, allowing the startup to develop a solution that addresses real-world hospital biology department needs.
Implementation Across Multiple Sites
The involvement of hospitals in Marseille, Lyon, and Limoges provides Kiro with diverse operational environments to test and refine its AI system. These major French healthcare institutions serve different patient populations and operate under varying clinical protocols, creating a robust testing ground for the technology. The geographic distribution of the project also positions the solution for potential wider adoption across French healthcare systems.
AI-assisted decision support tools in clinical settings have gained increasing attention in recent years, particularly in areas where standardized protocols can improve efficiency without compromising care quality. Biology test prescriptions represent an ideal use case, as these decisions often follow established clinical guidelines while still allowing room for optimization through data-driven insights.
Broader European Context
This initiative reflects a broader European trend of healthcare institutions partnering with technology companies to implement artificial intelligence solutions within hospital operations. Countries across the EU have been investing in digital health transformation, with particular emphasis on clinical decision support systems that can enhance efficiency while reducing costs. France has positioned itself as a leader in health tech innovation, with numerous startups and established companies developing AI applications tailored to hospital workflows.
The OPTIMABIO project exemplifies how European hospitals are moving beyond pilot projects toward sustained partnerships with startups to address specific operational challenges. As healthcare systems across Europe face increasing pressure to optimize resource utilization while maintaining quality care, similar collaborative initiatives between hospitals and technology providers are likely to become more common in the coming years.